BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 21136185)

  • 1. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
    Basu S; Saboury B; Torigian DA; Alavi A
    Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S; Zahid I; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
    Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the best way to diagnose and stage malignant pleural mesothelioma?
    Zahid I; Sharif S; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
    Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
    Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
    Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
    Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
    Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.
    Fodor A; Fiorino C; Dell'Oca I; Broggi S; Pasetti M; Cattaneo GM; Gianolli L; Calandrino R; Di Muzio NG
    Strahlenther Onkol; 2011 Nov; 187(11):736-43. PubMed ID: 22037650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
    Bénard F; Sterman D; Smith RJ; Kaiser LR; Albelda SM; Alavi A
    Chest; 1998 Sep; 114(3):713-22. PubMed ID: 9743156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loco-regional staging of malignant pleural mesothelioma by integrated
    Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
    Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
    Pilling J; Dartnell JA; Lang-Lazdunski L
    Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study.
    Botticella A; Defraene G; Nackaerts K; Deroose CM; Coolen J; Nafteux P; Peeters S; Ricardi U; De Ruysscher D
    Acta Oncol; 2016 Dec; 55(12):1450-1455. PubMed ID: 27732127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
    Fodor A; Broggi S; Incerti E; Dell'Oca I; Fiorino C; Samanes Gajate AM; Pasetti M; Cattaneo MG; Passoni P; Gianolli L; Calandrino R; Picchio M; Di Muzio N
    Clin Lung Cancer; 2019 Jan; 20(1):e29-e38. PubMed ID: 30253920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
    Huang YC; Tu DG; Wu JD; Lee MY
    Spine (Phila Pa 1976); 2009 Oct; 34(21):E780-3. PubMed ID: 19934799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.